Net margin is calculated as Net Income divided by its Revenue. Vivimed Labs's Net Income for the
three
months ended in Dec. 2025 was ₹-165.5 Mil. Vivimed Labs's Revenue for the
three
months ended in Dec. 2025 was ₹159.9 Mil. Therefore, Vivimed Labs's net margin for the quarter that ended in Dec. 2025 was -103.53%.
The historical rank and industry rank for Vivimed Labs's Net Margin % or its related term are showing as below:
NSE:VIVIMEDLAB'
s Net Margin % Range Over the Past 10 Years
Min: -175.59 Med: -10.04 Max: 17.47
Current: -41.8
NSE:VIVIMEDLAB's Net Margin % is ranked worse than 85.36% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs NSE:VIVIMEDLAB: -41.80
Vivimed Labs (NSE:VIVIMEDLAB) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Vivimed Labs Net Margin % Related Terms
Vivimed Labs Net Margin % Historical Data
* Premium members only.
The historical data trend for Vivimed Labs's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vivimed Labs's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivimed Labs Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vivimed Labs's Net Margin % distribution charts can be found below:
* The bar in red indicates where Vivimed Labs's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vivimed Labs (NSE:VIVIMEDLAB) has a Net Margin % of -103.53% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Vivimed Labs and its competitors. According to the industry distribution chart, Vivimed Labs ranks #816 out of 956 companies in the Drug Manufacturers industry, placing it in the top 85.4%.
Is Vivimed Labs' Net Margin % too high?
Vivimed Labs' current Net Margin % is -103.53%. Based on the distribution chart, Vivimed Labs ranks #816 out of 956 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vivimed Labs has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vivimed Labs' Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vivimed Labs ranks #816 out of 956 companies for Net Margin %. This places Vivimed Labs in the lower half of its industry. The industry median Net Margin % is 5.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Vivimed Labs and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivimed Labs's current Net Margin % is -103.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivimed Labs stock overvalued right now?
Based on GuruFocus' analysis, Vivimed Labs (NSE:VIVIMEDLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.57, compared to a current price of ₹5.71 — trading 122.2% above its estimated fair value. The current Net Margin % is -103.53%. Vivimed Labs' overall GF Score™ is 33/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Vivimed Labs (NSE:VIVIMEDLAB), the current Net Margin % is -103.53% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vivimed Labs (NSE:VIVIMEDLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Vivimed Labs stock appears to be overvalued.
The current stock price of ₹5.71 is trading 122.2% above its estimated GF Value™ of ₹2.57.
GuruFocus considers Vivimed Labs to be Significantly Overvalued.
Key valuation signals for NSE:VIVIMEDLAB:
Net Margin %: -103.53%
GF Value™: ₹2.57 vs. price of ₹5.71 (122.2% above fair value)
No single metric tells the full story. See the NSE:VIVIMEDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vivimed Labs Ltd is an India-based company that is engaged in the Business of Active pharmaceutical ingredients, Intermediates, Nutraceutical ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals, and Retail Branded Formulation manufacturing. The company has three reportable segments: the Speciality Chemicals Business, the Pharma Business, and others. The majority of revenue is earned through the Pharma business.
33GF Score
Get the complete analysis for NSE:VIVIMEDLAB
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VIVIMEDLAB has been successfully added to your 
